Telaprevir for previously untreated chronic hepatitis C virus infection
- Jacobson I. M.
- McHutchison J. G.
- Dusheiko G.
- Di Bisceglie A. M.
- Reddy K. R.
- Bzowej N. H.
- Marcellin P.
- Muir A. J.
- Ferenci P.
- Flisiak R.
- George J.
- Rizzetto M.
- Shouval D.
- Sola R.
- Terg R. A.
- Yoshida E. M.
- Adda N.
- Bengtsson L.
- Sankoh A. J.
- Kieffer T. L.
- George S.
- Kauffman R. S.
- Zeuzem S.
- ADVANCE Study Team: Gadano A.
- Terg R.
- Bell S.
- Cheng W.
- Crawford D.
- Dore G.
- George J.
- MacDonald G.
- Roberts S.
- Ferenci P.
- Gschwantler M.
- Laferl H.
- Maieron A.
- Heathcote J.
- Kaita K.
- Myers R.
- Sherman M.
- Yoshida E.
- Barange K.
- Couzigou P.
- Marcellin P.
- Pawlotsky J. M.
- Pol S.
- Serfaty L.
- Trépo C.
- Zarski J. P.
- Berg T.
- Buggisch P.
- Diepolder H.
- Goeser T.
- Mauss S.
- Rasenack J.
- Schmidt W.
- Wedemeyer H.
- Zeuzem S.
- Baruch Y.
- Ben Ari Z.
- Maor Y.
- Safadi R.
- Shouval D.
- Zuckerman E.
- ANDREONE, PIETRO
- Colombo M.
- Rizzetto M.
- Baka Cwierz B.
- Flisiak R.
- Gladysz A.
- Janczewska Kazek E.
- Jablkowski M.
- Krycka W.
- Diago M.
- Esteban Mur R.
- Sanchez Tapias J.
- Sola R.
- Brown A.
- Dusheiko G.
- Fox R.
- Afdhal N.
- Arora S.
- Bennett M.
- Bernstein D.
- Bloomer J.
- Bochan M.
- Bonkovsky H.
- Brady C.
- Brown R.
- Bzowej N.
- Cochran J.
- Chasen R.
- Davis G.
- De Jesus E.
- Di Bisceglie A.
- Dienstag J.
- Dieterich D.
- Etzkorn K.
- Everson G.
- Fried M.
- Freilich B.
- Ghalib R.
- Gitlin N.
- Godofsky E.
- Gordon S.
- Hassanein T.
- Jacobson I.
- Javadi F.
- Jonas M.
- Kilby A.
- Kwo P.
- Lawitz E.
- Lebovics E.
- Lee W.
- Luketic V.
- Maillard M.
- Monto A.
- Morgan T.
- Min A.
- Murphy M.
- Nelson D.
- Northup P.
- Nyberg L.
- Pockros P.
- Poordad F.
- Poulos J.
- Reddy R.
- Rodriguez Torres M.
- Satyanarayana R.
- Schiff E.
- Schwartz H.
- Shaikh O.
- Sheikh M.
- Sherman K.
- Smith J.
- Strohecker J.
- Sulkowski M.
- Szabo G.
- Te H.
- Terrault N.
- Tsai N.
- Vargas H.
- Vierling J.
- Wruble L.
- Younossi Z.
- Zein N.
DOIAbstract
BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients. METHODS: In this international, phase 3, randomized, double-blind, placebo-controlled trial, we assigned 1088 patients with HCV genotype 1 infection who had not received previous treatment for the infection to one of three groups: a group receiving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR group), followed by peginterferon-ribavirin alone for 12 weeks if HCV RNA was undetectable at weeks 4 and 12 or for...
Add to ORKG
